2 research outputs found
Practicing Sikhism in America
No full textThis session is part four of a six part series running through the 2018-2019 academic year titled Encountering Religious and Cultural Traditions: A Series Fostering Religious Literacy and Interreligious Understanding. In this session, Angela Madan and Randeep Ricky Singh Arora will teach about the lived experience of Sikhs in America as well as address some common misconceptions and stereotypes people have about the tradition.
Renowned scholar of religion Wilfred Cantwell Smith argued that in order to “understand Buddhists, we must not look at something called Buddhism but at the world so far as possible through Buddhist eyes.” Likewise, in order to understand Judaism, Hinduism, and so on, we must not look at Judaism, Hinduism and so on, but at the worldviews of Jews, Hindus, and so. In his New York Times Bestseller, Religious Literacy, Stephen Prothero writes “I am convinced that one needs to know something about the world’s religions in order to be truly educated,” and argues that “you need religious literacy in order to be an effective citizen.” This year-long series aims to foster religious literacy and interreligious understanding by examining the world through the eyes of religious scholars and practitioners from various traditions, especially our locally lived traditions in Minnesota. The presenters will share their own lived experiences of the traditions and address any common stereotypes and misconceptions.
Angela Madan and Randeep “Ricky” Singh Arora are Sikhs. The word Sikh means student who is learning for life and respect humanity. Madan has been a member of the Minnesota Sikh community for 20 years. Her life-long goal is “to follow a truthful way of life and to be actively involved in the communities in which I live.” Madan is a professional pharmacist. Arora serves as Secretary on the Board of the Sikh Society of Minnesota, prior to which he has served various leadership roles such as Vice-President, Secretary, Director of Outreach, and other volunteer positions since 1996. His focus is on the operations of the Gurdwara (place for congregational prayers), communications, and developing the co-curricular and multifaith activities of the Society. He also coaches and performs Punjabi folk dance Bhangra at various community events to teach about and strengthen inter-community relations. He is often an invited guest speaker on Sikhism at various local education and religious institutions. Arora holds a Master’s degree in Technology and is a professional Senior Technology Manager in St Paul. To make an accessibility request, call Disability Resources at (651) 962-631
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
No full textBackground GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701
